Loading
SARASOTA -- Rapid Pathogen Screening recently named Mark Myslinski as its newest chief executive officer.
Myslinski comes to RPS from Hologic Inc., a Massachusetts-based company with nearly $1.8 billion in revenues in its 2011 fiscal year, where he served as a vice president. Prior to that, he led Pittsburgh-based RedPath Integrated Pathology Inc. as president and CEO.
In late 2009, RPS spoke to the Business Review about the Adeno Detector, its patent-protected diagnostic test for conjunctivitis that works in as little as 10 minutes. At the time, the company projected it would achieve $5 million in annual revenues. (See “A Mighty Sight,” Sept. 24, 2009.)
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
